INDP
Indaptus Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.30
+1.85%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$3.26
From 52W high−30.53%
Volume111353.00
Market cap$439.70M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$3.26
From 52W high
−30.53%
Volume
111353.00
Market cap
$439.70M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−27.7x
P/E (TTM)
—
RSI (14)
54.6
MomentumView details →
1D Return
+1.85%
YTD Return
+10.14%
SummaryUpdated Jun 1, 2026
Indaptus Therapeutics, Inc. (NASDAQ:INDP) is a pre-clinical biotechnology company founded in 2021 and headquartered in New York, New York. The company was formerly known as Intec Parent, Inc. before changing its name to Indaptus Therapeutics in August 2021. As a development-stage biopharmaceutical company, Indaptus focuses on creating innovative immunotherapy treatments for cancer and viral infections, with its lead candidate currently in Phase I clinical trials.
Similar companies
Latest newsMore news →
Indaptus Therapeutics, Inc. amended its Stock Purchase Agreement to extend the outside closing date for its approximately $24.0 million private placement of common stock from September 29, 2026 to October 16, 2026.36d agoIndaptus Therapeutics, Inc. signed a private placement to issue 20,338,974 shares for aggregate gross proceeds of approximately $24.0 million.56d agoTim Ruan resigned as Director of the Board of Directors of Indaptus Therapeutics, Inc., effective September 2, 2026.61d ago